Andrew D. Jones
Net Worth

Last updated:

What is Andrew D. Jones net worth?

The estimated net worth of Mr. Andrew D. Jones is at least $1,075,000 as of 6 Dec 2021. He owns shares worth $122,120 as insider and has received compensation worth at least $952,880 in NovaBay Pharmaceuticals, Inc..

What is the salary of Andrew D. Jones?

Mr. Andrew D. Jones salary is $238,220 per year as Chief Financial Officer & Treasurer in NovaBay Pharmaceuticals, Inc..

How old is Andrew D. Jones?

Mr. Andrew D. Jones is 54 years old, born in 1971.

What stocks does Andrew D. Jones currently own?

As insider, Mr. Andrew D. Jones owns shares in one company:

Company Title Shares Price per share Total value
NovaBay Pharmaceuticals, Inc. (NBY) Chief Financial Officer & Treasurer 127,461 $0.96 $122,120

What does NovaBay Pharmaceuticals, Inc. do?

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Andrew D. Jones insider trading

NovaBay Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 36,765 $0.44 $16,177
Purchase
Common Stock 8,690 $0.44 $3,824

NovaBay Pharmaceuticals key executives

NovaBay Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: